» Articles » PMID: 39715901

Leucine Zipper-based Immunomagnetic Purification of CAR T Cells Displaying Multiple Receptors

Abstract

Resistance to chimaeric antigen receptor (CAR) T cell therapy develops through multiple mechanisms, most notably antigen loss and tumour-induced immune suppression. It has been suggested that T cells expressing multiple CARs may overcome the resistance of tumours and that T cells expressing receptors that switch inhibitory immune-checkpoint signals into costimulatory signals may enhance the activity of the T cells in the tumour microenvironment. However, engineering multiple features into a single T cell product is difficult because of the transgene-packaging constraints of current gene-delivery vectors. Here we describe a cell-sorting method that leverages leucine zippers for the selective single-step immunomagnetic purification of cells co-transduced with two vectors. Such 'Zip sorting' facilitated the generation of T cells simultaneously expressing up to four CARs and coexpressing up to three 'switch' receptors. In syngeneic mouse models, T cells with multiple CARs and multiple switch receptors eliminated antigenically heterogeneous populations of leukaemia cells coexpressing multiple inhibitory ligands. By combining diverse therapeutic strategies, Zip-sorted multi-CAR multi-switch-receptor T cells can overcome multiple mechanisms of CAR T cell resistance.

Citing Articles

Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy.

Zhang B, Wu J, Jiang H, Zhou M Cells. 2025; 14(5).

PMID: 40072049 PMC: 11899321. DOI: 10.3390/cells14050320.

References
1.
June C, Sadelain M . Chimeric Antigen Receptor Therapy. N Engl J Med. 2018; 379(1):64-73. PMC: 7433347. DOI: 10.1056/NEJMra1706169. View

2.
Mikkilineni L, Kochenderfer J . CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2020; 18(2):71-84. DOI: 10.1038/s41571-020-0427-6. View

3.
Berger T, Maus M . Mechanisms of response and resistance to CAR T cell therapies. Curr Opin Immunol. 2021; 69:56-64. DOI: 10.1016/j.coi.2021.02.010. View

4.
Majzner R, Mackall C . Tumor Antigen Escape from CAR T-cell Therapy. Cancer Discov. 2018; 8(10):1219-1226. DOI: 10.1158/2159-8290.CD-18-0442. View

5.
Labanieh L, Mackall C . CAR immune cells: design principles, resistance and the next generation. Nature. 2023; 614(7949):635-648. DOI: 10.1038/s41586-023-05707-3. View